combretastatin a1

Combretastatin A1 phosphate, a potent vascular disruptive agent, exhibits anti-angiogenic effects on tumors and holds potential for research on pancreatic neuroendocrine tumors.

Combretastatin A-1 is a potent microtubule inhibitor with anti-tumour and anti-vascular activity, acting through microtubule protein depolymerisation-mediated inactivation of AKT to inhibit the Wnt β-catenin pathway, and can be used to study hepatocellular carcinoma.

Combretastatin A-1 phosphate (OXi-4503) tetrasodium, a prodrug of Combretastatin A-1, is a tubulin-binding microtubule polymerization inhibitor targeting the colchicine-binding site. By inducing tubulin depolymerization, it inhibits the Wnt β-catenin pathway and deactivates AKT, possessing both anti-tumor and anti-vascular properties.

Oxi0-4503 (currently termed combretastatin A1 phosphate) is a diphosphate prodrug of combretastatin A1. As a second-generation vascular disrupting agent in the combretastatin family, it demonstrates significant activity in disrupting vascular structures.